CSL Wins HAE Race For U.S. FDA Approval; Will Orphan Drug Rules Lock The Gate Behind?

PERTH, Australia - CSL Behring, a U.S. subsidiary of the Australian-headquartered CSL Limited, announced U.S. FDA approval Oct. 12 of its C1 esterase inhibitor Berinert for treating adults and adolescents with acute abdominal or facial attacks of hereditary angioedema (HAE)